J. Corominas

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

A. Borobia, B. Clotet, J. Prado, 2022, The Lancet Regional Health - Europe.

Preclinical efficacy, safety, and immunogenicity of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2022 .

Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2021 .

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2021, bioRxiv.